BofA analyst Tazeen Ahmad downgraded Sarepta (SRPT) to Underperform from Neutral with a $10 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Hold Rating on Sarepta Therapeutics Amid Regulatory Challenges and Uncertain Future for Elevidys
- Wainwright Analyst Slaps $0 Price Target on Sarepta Stock (SRPT)
- FDA official sees ‘arduous’ path back for Sarepta’s Elevidys, STAT reports
- Netflix downgraded, Intel initiated: Wall Street’s top analyst calls
- JPMorgan downgrades Sarepta on unknown Elevidys timelines